--- title: What Is Graft-versus-Host Disease (GVHD)? url: "https://www.yyhmedical.com/en/faq/hsct-gvhd/what-is-gvhd" type: FAQPage inLanguage: en-US --- # What Is Graft-versus-Host Disease (GVHD)? > GVHD develops when donor immune cells recognize and attack normal recipient tissues after allo-HSCT. It can damage the skin, intestines, liver, lungs, and other organs. ## What Is Graft-versus-Host Disease (GVHD)? Overview: Graft-versus-host disease (GVHD) is one of the important complications that require particular attention after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients and families sometimes refer to it as a “rejection reaction,” although GVHD specifically involves donor immune cells attacking the recipient’s tissues. During allo-HSCT, a patient receives healthy blood-forming stem cells from a donor. Because donor and recipient differ immunologically and genetically, immune cells originating from the donor may recognize the patient’s normal tissues as foreign. The resulting immune attack can injure the skin, intestines, liver, lungs, and other organs.  **Why can GVHD develop after transplantation?** Allogeneic HSCT is an important treatment option for selected blood cancers and other hematologic disorders. Unlike autologous transplantation, which uses a patient’s own cells, allogeneic transplantation uses stem cells from another person. After infusion, these cells gradually establish a new blood-forming and immune system in the recipient. However, donor immune cells entering the patient’s body may not fully adapt to their new environment because of immunogenetic differences. Immune cells normally identify and eliminate abnormal cells, but in this setting they can mistakenly regard normal recipient tissues as foreign and attack them. When the immune reaction causes significant tissue injury, GVHD develops. The skin, gastrointestinal tract, liver, and lungs are among the organs that may be affected. **How can GVHD affect the transplant outcome?** GVHD is a major complication to prevent and manage after allo-HSCT. Severe disease can reduce quality of life, increase infection risk, and even affect survival. Yet donor immunity also has a potentially beneficial role: donor immune cells may recognize and attack residual leukemia cells, a response called the graft-versus-leukemia (GVL) effect. For this reason, transplant care does not simply aim to eliminate every immune response. Instead, clinicians seek to limit harmful attacks on normal tissues while preserving beneficial anti-cancer activity where possible. **Which organs are commonly affected?** - **Skin:** Rash, redness, and itching may occur. Skin is among the most frequently affected organs. - **Intestines:** Nausea, vomiting, and diarrhea may occur; severe intestinal involvement can cause blood in the stool. - **Liver:** GVHD may cause abnormal liver-function tests, including increased bilirubin. - **Other organs:** Chronic GVHD can also affect the mouth, lungs, gastrointestinal tract, muscles, and joints, potentially influencing everyday life over the long term. **Will everyone develop GVHD?** No. Although GVHD is a recognized complication of allo-HSCT, it does not occur in every patient. Risk depends on multiple factors, including the degree of donor–recipient HLA matching, donor and recipient characteristics, the transplant regimen, and infections. Advances in donor selection, conditioning regimens, and supportive transplant care have improved prevention and management. The transplant team selects preventive and treatment strategies based on each patient’s situation. **Does developing GVHD mean the transplant has failed?** No. GVHD is not the same as transplant failure. In some situations, mild GVHD may occur alongside a stronger GVL response and may be associated with a lower relapse risk. However, excessive GVHD can seriously damage organs and needs prompt treatment. The goal remains to control harmful immune injury while retaining useful anti-disease effects where possible. **How can patients help prevent and recognize GVHD?** Long-term follow-up after transplantation is essential. Attend scheduled appointments and pay attention to new changes in your health. Contact the transplant team promptly if you notice a new rash, redness, or itching; persistent nausea, vomiting, or diarrhea; pronounced dryness of the eyes or mouth; unexplained fatigue; or breathing symptoms. Early identification, assessment, and appropriate treatment can reduce the risk of progression. **Summary** GVHD develops when donor immune cells recognize and attack normal recipient tissues after allo-HSCT. It can damage the skin, intestines, liver, lungs, and other organs. Some donor immune activity may also contribute to the GVL effect, but severe GVHD is harmful. Prevention, early recognition, and appropriate treatment can support safer recovery. ## Related questions ### Q1: Does GVHD mean my transplant has failed? No. GVHD is a recognized complication of allo-HSCT, not proof of failure. Mild GVHD can sometimes accompany an anti-cancer immune response, whereas severe GVHD requires active treatment. ### Q2: Why would donor cells attack my own body? After entering the recipient, donor immune cells can recognize immunologic differences between donor and recipient. If that response becomes excessive, they may attack the patient’s normal tissues. ### Q3: Can GVHD be prevented? Its risk can be reduced. The transplant team uses measures such as appropriate donor selection, transplant-regimen planning, and preventive medication. ### Q4: Can GVHD still be treated after it develops? Yes. Depending on severity and the organs involved, clinicians may use immunosuppressive medication, supportive care, and other individualized treatments. ## Content attribution (YMYL) - Author: - Medically reviewed by: - Last reviewed: - First published: > --- Original (HTML):https://www.yyhmedical.com/en/faq/hsct-gvhd/what-is-gvhd This is a clean Markdown mirror for large language models; the original page is authoritative.